

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-52) OPORTUZUMAB MONATOX
 PRONUNCIATION oh" por tooz' ue mab moe' na tox
 THERAPEUTIC CLAIM Treatment of cancer

CHEMICAL NAMES

1. Immunoglobulin G, anti-(tumor antigen 17-1A) (human-mouse single chain fragment) fusion protein with 252-608-exotoxin A (synthetic *Pseudomonas*)
2. Immunoglobulin scFv fusion protein, anti-[*Homo sapiens* tumor-associated calcium signal transducer 1 (TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP2, epithelial cell adhesion molecule Ep-CAM, KSA, KS1/4 antigen, M4S1, tumor antigen 17-1A, CD326)] humanized monoclonal antibody scFv fused with *Pseudomonas aeruginosa* exotoxin A; hexahistidyl -humanized scFv [V-KAPPA (*Homo sapiens* IGKV1-39*01 (78%)- IGKJ1*01, I126>L) [11.3.9] (7-118) -26-mer linker -VH (*Homo sapiens* IGHV7-4-1*02 -(IGHD)-IGHJ4*01, V124>L) [8.8.9] (145-260)] -20-mer linker -*Pseudomonas aeruginosa* exotoxin A (ETA) [277-633 precursor fragment, containing domain II (281-393) with furin proteolytic cleavage site (302-313), domain Ib (394-433), domain III (434-637)] (281-637) -hexahistidyl-lysyl-aspartyl-glutamyl-leucyl

STRUCTURAL FORMULA

scFv fusion protein

HHHHHHDIQM	TQSPSSLSAS	VGDRVITICR	STKSLLSNSG	ITYLYWYQQK	50
PGKAPKLLIY	QMSNLASGVP	SRFSSSGSGT	DFTLTISSLQ	PEDFATYYCA	100
QNLEIPRTFG	QGTKVELKRA	TPSHNSHQVP	SAGGPTANSQ	TSGSEVQLVQ	150
SGPGLVQPGG	SVRISCAASG	YTFTNYGMNW	VKQAPGKGLE	WMGWINTYTG	200
ESTYADSFKG	RFTFSLD TSA	SAAYLQINSL	RAEDTAVYYC	ARFAIKGDYW	250
GQGTLLTVSS	EFGGAPEFPK	PSTPPGSSGL	EGGSLAALTA	HQACHLPLET	300
FTRHRQPRGW	EQLEQCGYPV	QRLVALYLAA	RLSWNQVDQV	IRNALASPGS	350
GGDLGEAIRE	QPEQARLALT	LAAAESERFV	RQGTGNDEAG	AASADVSLT	400
CPVAAGECAG	PADSGDALLE	RNYPTGAEFL	GDGGDVSFST	RGTQNWTVR	450
LLQAHRLQEE	RGYVFGYHG	TFLEAAQSIV	FGGVRARSQD	LDAIWRGFYI	500
AGDPALAYGY	AQDQEPDARG	RIRNGALLRV	YVPRSSLPGF	YRTGLTLAAP	550
EAAGEVERLI	GHPLPLRLDA	ITGPEEEGGR	LETILGWPLA	ERTVVIPSAI	600
PTDPRNVGGD	LDPSSIPDKE	QAISALPDYA	SQPGKPPHHH	HHHKDEL	647

Disulfide bridges

29-99 166-240 294-316 401-408

Glycosylation sites (N)

445

MOLECULAR FORMULA

C₃₀₇₂H₄₇₃₁N₈₇₇O₉₅₂S₁₂

MOLECULAR WEIGHT

69.57 kDa

TRADEMARKS	Vicineum, Proxinium
SPONSOR	Sesen Bio
CODE DESIGNATIONS	VB4-845, 4D5MOCB-ETA
<u>CAS</u> REGISTRY NUMBER	945228-48-8
UNII	945CY7ZMI2
WHO NUMBER	9045

gbk